The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•27 March 2026•

1 min read

Lantern Pharma Receives FDA Clearance for Pediatric Cancer Clinical Trial

Key Facts

1Lantern Pharma and Starlight Therapeutics received FDA clearance for a Phase 1 clinical trial of STAR-001.

2The planned clinical trial targets pediatric Central Nervous System (CNS) cancer.

Lantern Pharma and its subsidiary Starlight Therapeutics have received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application. This approval allows the companies to initiate a Phase 1 clinical trial for STAR-001, a drug candidate designed to treat pediatric Central Nervous System (CNS) cancer. The trial will focus on evaluating the safety and efficacy of the treatment in children with rare brain and CNS tumors. This regulatory milestone marks a significant transition for STAR-001 from preclinical development to human clinical testing. Investors typically view such developments positively, as they validate the company's research pipeline and move the therapy closer to potential commercialization. Shares of Lantern Pharma (LTRN) may see increased activity following this announcement as the company expands its clinical-stage portfolio.